The endocannabinoid (eCB) system is the target of drugs and supplements like cannabidiol (CBD) and cannabis.
Synonyms:
eCB
Related Articles:
- Targeting the Endocannabinoid System in Adult Fragile X MiceWith a $90,000 grant from the FRAXA Research Foundation from 2013-2014, Dr. Andres Ozaita led a team to test rimonabant's ability to blockade the CB1 receptor. Blocking CB1 has shown potential to reverse most symptoms of disease in mice bred to mimic Fragile X syndrome.
- Cellular-Specific Therapeutic Targeting of Inhibitory Circuits in Fragile X SyndromeStudies have shown that the function of inhibitory networks is disturbed in Fragile X. This abnormality is not well understood but appears to be secondary to abnormalities in metabotropic glutamate and endocannabinoid systems. With a $90,000 grant from FRAXA, Dr. Molly Huntsman’s team examined how these networks interact and how inhibitory deficits can best be remedied.
- The Endocannabinoid System in a Mouse Model of Fragile X SyndromeWith a $128,500 grant over 2011-2013 from FRAXA Research Foundation, Drs. Bradley Alger and Ai-Hui Tang at the University of Maryland researched endocannabinoid pathways in Fragile X.
- Understanding and Reversing Hypersensitivity to Sounds in Fragile X SyndromeWith a $90,000 grant from FRAXA Research Foundation over 2018-2019, Drs. Devin Binder, Iryna Ethell, and Patricia Pirbhoy at the University of California at Riverside aim to understand - and reverse - hypersensitivity to sound in Fragile X syndrome.
- Zygel May Improve Behavior in Children With Severe Fragile X, Trial Data SuggestZynerba presented clinical trial results for Zygel at a recent neurology conference. Zygel, an experimental cannabidiol (CBD) gel, may reduce behavioral abnormalities in children with Fragile X syndrome who have more severe disease.